A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease

Chagas disease (ChD), caused by the hemoflagellate parasite Trypanosoma cruzi, affects six to seven million people in Latin America. Lately, it has become an emerging public health concern in nonendemic regions such as North America and Europe. There is no prophylactic or therapeutic vaccine as yet,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Vaccines
Autors principals: Portillo, Susana, Zepeda, Brenda G., Iniguez, Eva, Olivas, Janet J., Karimi, Nasim H., Moreira, Otacilio C., Marques, Alexandre F., Michael, Katja, Maldonado, Rosa A., Almeida, Igor C.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6430786/
https://ncbi.nlm.nih.gov/pubmed/30911415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-019-0107-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars